Overview MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED) Status: Terminated Trial end date: 2007-11-01 Target enrollment: Participant gender: Summary MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease. Phase: Phase 2 Details Lead Sponsor: Merck Sharp & Dohme Corp.